Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salsalate in mild to moderate Alzheimer's disease
NCT03277573Phase 1Completed
- Start
- Jul 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Salsalate Arm with Placebo Arm (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 months. Started Jul 2017; status: completed.
02
Drugs
Amigesic
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03277573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277573.